Global Viscosupplementation Market Segmentation, By Source (Animal Origin And Non-Animal Origin), Age Group (Geriatric And Adults), Injection (Single Injection, Three Injections, and Five Injections), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight, and High Molecular Weight), End User (Hospital, Orthopedic Clinics, Ambulatory Care Centers, and Others), Distribution Channel (Direct Tender And Retail Sales) – Industry Trends and Forecast to 2031
Viscosupplementation Market Analysis
The viscosupplementation market is witnessing significant growth, driven by the rising prevalence of osteoarthritis and other joint disorders that necessitate effective pain management solutions. Viscosupplementation involves the injection of hyaluronic acid (HA) into joints to improve lubrication, reduce pain, and enhance mobility. Recent advancements in formulation technologies have led to the development of more effective and longer-lasting viscosupplementation products, catering to the diverse needs of patients. For instance, new cross-linking techniques and the introduction of bioengineered HA products have improved the viscosity and elasticity of these injections, resulting in better patient outcomes. Furthermore, increasing awareness among healthcare professionals regarding the benefits of viscosupplementation is promoting its adoption in clinical practice. The expansion of distribution channels, including online platforms, is also making these treatments more accessible to patients. In addition, ongoing research into combination therapies, which integrate viscosupplementation with other treatment modalities, is expected to further enhance market growth. Overall, the viscosupplementation market is poised for continued expansion, fueled by technological innovations and a growing patient population seeking effective solutions for joint-related ailments.
Viscosupplementation Market Size
The global viscosupplementation market size was valued at USD 1.53 billion in 2023 and is projected to reach USD 2.94 billion by 2031, with a CAGR of 8.50% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Viscosupplementation Market Trends
“Increasing Preference for Single-Injection Formulations”
The viscosupplementation market is witnessing significant growth, driven by the rising prevalence of osteoarthritis and other joint disorders that necessitate effective pain management solutions. One prominent trend in the global viscosupplementation market is the increasing preference for single-injection formulations over traditional multi-injection regimens. Such shift is largely driven by patient convenience and compliance, as single-injection products reduce the need for multiple visits to healthcare providers. For instance, the introduction of Durolane, a single-injection hyaluronic acid treatment for knee osteoarthritis, has gained popularity due to its effectiveness and the convenience it offers patients. In addition, the growing emphasis on minimally invasive procedures in orthopedic care is propelling the demand for these innovative solutions. As more patients seek effective, convenient treatments for osteoarthritis and joint pain, the adoption of single-injection viscosupplementation products is expected to drive significant growth in the global market, enhancing patient satisfaction and treatment outcomes.
Report Scope and Viscosupplementation Market Segmentation
|
Attributes
|
Viscosupplementation Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Anika Therapeutics, Inc. (U.S.), SEIKAGAKU CORPORATION (Japan), Bioventus (U.S.), Fidia Farmaceutici S.P.A (Italy), Ferring B.V (Netherlands), sanofi-aventis U.S. LLC (U.S.), Zimmer Biomet (U.S.), OrthogenRx, Inc. (a subsidiary of AVNS) (U.S.), APTISSEN (France), Johnson & Johnson Services, Inc. (U.S.), LG Chem. (South Korea), Viatris Inc. (U.S.), IBSA Institut Biochimique SA (Switzerland), Ortobrand International (U.S.), TRB CHEMEDICA SA (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Lifecore (a subsidiary of Landec Corporation) (U.S.), VIRCHOW BIOTECH (India), and Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals) (India)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Viscosupplementation Market Definition
Viscosupplementation is a medical treatment that involves the injection of a gel-like substance, typically hyaluronic acid, into a joint space, most commonly the knee. This procedure is designed to restore the viscosity and elasticity of synovial fluid, which can help lubricate the joint, reduce pain, and improve mobility in individuals suffering from osteoarthritis or joint injuries. By providing cushioning and enhancing joint function, viscosupplementation aims to alleviate discomfort and improve the overall quality of life for patients with degenerative joint conditions.
Viscosupplementation Market Dynamics
Drivers
- Rising Geriatric Population
As the population ages, there is a corresponding rise in the number of elderly patients admitted to hospitals due to serious traumatic injuries. This increase in age-related health issues, particularly knee osteoarthritis, is driving a higher demand for both diagnosis and treatment options. The growing elderly population puts additional pressure on healthcare systems, necessitating more effective care, services, and technologies to prevent and manage knee osteoarthritis, along with related conditions such as sarcopenia, osteoporosis, and osteopenia. Older individuals are particularly susceptible to these ailments, resulting in weakened bones and joints. In these cases, viscosupplementation is increasingly utilized to provide immediate and effective relief for patients. Consequently, as the prevalence of osteoarthritis rises and the need for early diagnosis intensifies, the demand for viscosupplementation treatments is expanding significantly within the global healthcare landscape, making it a crucial market driver.
- Rising Susceptibility to Osteoporosis and Osteoarthritis
Osteoporosis is a bone disease characterized by decreased bone mineral density and mass, along with changes in bone quality or structure, which increases the risk of fractures due to weakened bones. This condition is more prevalent in women, particularly post-menopausal women, who often experience fractures as osteoporosis is a silent disease that typically shows no symptoms. Elderly individuals are also at a higher risk for developing osteoporosis. In contrast, osteoarthritis is a joint disorder marked by inflammation of the joints and surrounding tissues, significantly impairing mobility. These silent conditions lead to weakened bones and joints, resulting in serious consequences such as spinal deformities, fractures, and sudden falls. Consequently, the rising prevalence of osteoporosis and osteoarthritis directly boosts the demand for viscosupplementation treatments aimed at addressing complications arising from these conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive growth in the global viscosupplementation market.
Opportunities
- Safety and Efficacy of Intra-Articular Hyaluronic Acid (IAHA)
Various types of hyaluronic acid injections, commonly referred to as viscosupplementation, are utilized for treating knee osteoarthritis. These injections are derived either from rooster or chicken combs or produced through bacterial fermentation, and they are administered directly into the joint. Intra-articular hyaluronic acid (IAHA) is an FDA-approved treatment for knee osteoarthritis, offering a localized therapeutic option that provides symptomatic relief without the systemic adverse effects commonly associated with intra-articular corticosteroids. Multiple randomized controlled trials (RCTs) and meta-analyses have evaluated the efficacy and safety of IAHA, yielding mixed findings. However, IAHA has been shown to positively impact pain management and improve joint function. In addition, there is growing evidence that multiple courses of IAHA can influence long-term outcomes, such as reducing the reliance on analgesics and delaying the necessity for total knee replacement surgery. This demonstrates a significant market opportunity for viscosupplementation, as the increasing adoption of IAHA in treatment regimens can enhance patient outcomes and expand the market.
- Increasing Investment in Research and Development (R&D)
Investment in research and development (R&D) for viscosupplementation is critical for exploring new applications and enhancing existing products, presenting significant market opportunities. As the understanding of joint health and the mechanisms of osteoarthritis evolves, R&D can facilitate the development of advanced formulations with improved efficacy and reduced side effects. For instance, ongoing research into bioengineered hyaluronic acid derivatives aims to create longer-lasting effects and better integrate with joint tissues, which could significantly improve patient outcomes. In addition, R&D efforts focused on combinations of viscosupplementation with other treatment modalities, such as platelet-rich plasma (PRP) therapy, are showing promising results in clinical trials. These advancements expand the therapeutic potential of viscosupplementation and attract investment and partnerships, ultimately enhancing market reach. Therefore, the commitment to R&D in the viscosupplementation sector represents a vital opportunity for growth and innovation in addressing joint disorders and improving patient care.
Restraints/Challenges
- Lack of Technical Expertise
Finding, attracting, and hiring talent is essential for building a skilled bench of engineers and technicians, but this process poses significant challenges. The manufacturing workforce is aging rapidly, leading to a wave of retirements, while the medical industry faces a shortage of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and those with undergraduate or postgraduate qualifications (engineers) remains high, the supply of qualified individuals is dwindling, particularly for complex procedures such as viscosupplementation that require trained professionals. Moreover, assembling a competent additive manufacturing (AM) workforce goes beyond recruitment; employees must continually update their skills as technology evolves. Many recent engineering graduates lack AM-specific training, making it difficult for employers to find candidates with the necessary expertise. This shortage of technical skills is thus a significant constraint on market growth.
- Stringent Government Regulations
The global commercialization of viscosupplementation by various key market players is contingent upon compliance with regulatory frameworks established in different countries. Pre-market approval processes for medical devices vary significantly across regions, with the U.S. Food, Drug, and Cosmetic Act (FD&C Act) governing medical devices in the United States, while the European Union oversees regulations in Europe. In addition, the rapid evolution of privacy policies and regulations in the Asia-Pacific and EMEA regions, including countries such as India, Russia, China, South Korea, Singapore, Hong Kong, and Australia, further complicates compliance. Viscosupplementation is regulated by a comprehensive structure of laws and guidelines designed to protect patients from potentially harmful treatments. While viscosupplementation serves as a vital intervention for damaged, injured, or infected body parts in cases of osteoarthritis and sports injuries helping to maintain patient mobility any misguidance in its application can jeopardize patient safety and bodily integrity. Therefore, the stringent rules and regulations governing the use of viscosupplementation may pose a significant challenge to market growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Viscosupplementation Market Scope
The market is segmented on the basis of type, treatment, diagnosis, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Source
- Animal Origin
- Non-Animal Origin
Age Group
- Geriatric
- Adults
Injection
- Single Injection
- Three Injections
- Five Injections
Molecular Weight
- Intermediate Molecular Weight
- Low Molecular Weight
- High Molecular Weight
End User
- Hospital
- Orthopedic Clinics
- Ambulatory Care Centers
- Others
Distribution Channel
- Direct Tender
- Retail Sales
Viscosupplementation Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is leading the market primarily due to the presence of key players in the industry and its status as the largest consumer market, supported by a high GDP. The U.S. is projected to experience significant growth, driven by advancements in drug treatments and innovative healthcare technologies that enhance patient outcomes. In addition, a robust healthcare infrastructure and substantial investment in research and development further contribute to the region's dominance in the ear and nasal packing market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Viscosupplementation Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Viscosupplementation Market Leaders Operating in the Market Are:
- Anika Therapeutics, Inc. (U.S.)
- SEIKAGAKU CORPORATION (Japan)
- Bioventus (U.S.)
- Fidia Farmaceutici S.P.A (Italy)
- Ferring B.V (Netherlands)
- sanofi-aventis U.S. LLC (U.S.)
- Zimmer Biomet (U.S.)
- OrthogenRx, Inc. (a subsidiary of AVNS) (U.S.)
- APTISSEN (France)
- Johnson & Johnson Services, Inc. (U.S.)
- LG Chem. (South Korea)
- Viatris Inc. (U.S.)
- IBSA Institut Biochimique SA (Switzerland)
- Ortobrand International (U.S.)
- TRB CHEMEDICA SA (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Lifecore (a subsidiary of Landec Corporation) (U.S.)
- VIRCHOW BIOTECH (India)
- Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals) (India)
Latest Developments in Viscosupplementation Market
- In November 2022, Anika Therapeutics Inc., a prominent company specializing in joint preservation healthcare, successfully completed a phase-3 clinical trial focused on a single primary endpoint. This medication is specifically designed for individuals suffering from severe knee osteoarthritis. The company is now concentrating on obtaining FDA approval for its treatment and seeking clearance for use in the global market
- In June 2022, Johnson and Johnson released new findings from phase-3 trials demonstrating that patients treated with their medications experienced better and more consistent long-term outcomes over two years while managing active psoriatic arthritis
- In May 2022, Fidia Farmaceutici SPA successfully leveraged the regenerative properties of hyaluronic acid (HA) through its innovative product portfolio, which was introduced in Spain. This portfolio aims to enhance tissue repair and promote healing in various medical applications. By harnessing the unique benefits of HA, Fidia is positioning itself as a leader in the regenerative medicine market
- In April 2022, Kolen Life entered into a partnership with Juniper Biologics to develop and commercialize TissueGene-C low dose, an innovative therapy for knee osteoarthritis. This treatment is delivered as a single intra-articular injection and does not necessitate surgical intervention
- In May 2021, Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation introduced JOYCLU, a 30mg intra-articular injection designed to enhance joint function. Seikagaku received manufacturing and marketing approval for this product in Japan in March 2021
SKU-